Customer No.: 20462 Attorney Docket No.: PU60400 Confirmation No.:6150

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Busch-Petersen et al.

 Serial No.:
 10/565,049
 Group Art Unit: 1625

 Filed:
 17 January 2006
 Examiner: O'Dell, D.

For: 2.2 – Substituted-3-Ethyl-Tropane Muscarinic Acetylcholine Receptor

Antagonists (as amended)

Commissioner for Patents P.O. Box 1450

P.O. DOX 143

Alexandria, VA 22313-1450

## FILING OF A FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.§1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper.

Please note that WIPO publication WO 2000/006545 has a corresponding US publication (US 2003/073690) and two US Patents, of which the 2 US patents are cited on the enclosed PTO1449 Form, e.g., US 6,455,527 and US 6,262,066. Also, Van Rossom, et al. is enclosed as the best available copy.

This statement is being filed within the time period specified in 37 CFR  $\S1.97(b)$ . No fee is required.

Respectfully submitted,

Dara L. Dinner

Attorney for Applicants Registration No. 33,680

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5017 Facsimile (610) 270-5090

GROUP ART UNIT

1625

Form PTO-1449 U.S. Department of Commerce ATTY. DOCKET NO. SERIAL NO Patent and Trademark Office PU60400 10/565,049 INFORMATION DISCLOSURE STATEMENT APPLICANT Belmonte, et al.

FILING DATE

BY APPLICANT (Use several sheets if necessary)

17 January 2006

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6,455,527	24 Sep 02	Tulshian, et al.			
	6,262,066	17 Jul 01	Tulshian, et al.			
	6,248,752	19 Jun 01	Smith			
	6,350,758	26 Feb 02	Kozikowski, et al.			
	2,800,481	23 Jul 57	Zirkle, et al.			
	2,800,478	23 Jul 57	Zirkle, et al.			

FOREIGN PATENT DOCUMENTS Document Number Date Country Class Subclass Translation Yes No

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Brown, History and Basic Properties, Humana Press, USA pgs 7-9 (1989)
	Caulfield, Pharmac. Ther., Vol. 58 pgs 319-79 (1993)
	Costello, et al., American Journal of Physiology, Vol. 276 (5) pgs L709-L714 (1999)
	Fryer and Jacoby, Am J Respir Crit Care Med, Vol. 158 (5, pt 3) pgs 154-60 (1998)
	Fryer et al., Life Sci, Vol. 64 (6-7) pgs 449-55 (1999)
	Hegke, et al., Life Sciences, Vol. 64 (6/7) pgs 419-428 (1999)
	Ikeda, et al., Naunyn-Schmiedeberg's Arch Pharmacol., Vol. 366, pages 97-103, (2002)
	Minette, et al., Journal of Applied Physiology, Vol. 67(6) pgs 2461-2465 (1989)
	Oprins, et al., Annals of the New York Academy of Sciences, Vol. 915 pgs. 102-106 (2000)
	Pauwels et al., Am. J. Respir. Crit. Care Med., Vol. 163 pgs1256-1276 (2001)
	Ran, et al., Yaoxue Xuebao, Vol. 19 (5) pgs 361-366 (1984) ABSTRACT only
	Sarau, et al. Am. Soc. Pharma. Exp. Ther., Vol. 56 pgs 657-663 (1999)
	Van Rossum, et al., Arch. Int., Pharmacodyn. Vol. 143 (3-4) pgs 299-330 (1963)
	Wu, et al., Zhongguo Yaowu Huazue Zazhi, Vol. 3 (1) pgs 23-26 (1993)ABSTRACT only
	Zirkle, et al., J Med Chem, Vol. 27 pgs 1269-1279 (1962)
	Zirkle, et al., J Med Chem, Vol. 27 pgs 1279-1285 (1962)
	Zirkle, et al., J Med Chem, Vol. 5 pgs 341-356 (1962)
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.